Clovis Oncology, Inc. CLVS

8.90$ Close Today. Sure

Triple 8.88$$$

Something NEW is Cooking. #CLVS#.

Let’s Gooooooo!!!!

A big question? Because they ignored the approval yesterday by FRANCE (sDNA-Rubracca) and his acquisition in the sector. How big news in NYSE. This is an extraordinary information for CLlVS and there's no reaction.....

With all this news. Draw your conclusions.
##$$CLVS##$$

Enjoy.

Greetings.

TODAY IN FRANCE.

Clovis Oncology Announces Availability And Reimbursement For Rubraca® (Rucaparib) Tablets For Women With Relapsed Ovarian Cancer In France

• Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type
• Rucaparib provided statistically significant improvement in progression-free survival (PFS) versus placebo in all ovarian cancer patients studied1
• Some patients with residual disease at ARIEL3 study entry who were treated with rucaparib showed further reduction in tumor burden, including complete responses1
• Most common Grade ≥3 adverse reaction was anemia; the only serious adverse reaction occurring in >2 percent of patients was anemia2
• Rucaparib now available in multiple countries across Europe.

Patrick J Mahaffy, Clovis Oncology's President and CEO and a director of the company, just received 250,000 options from the company. The strike price of the options received was $8.39, and these expire on February 03, 2030. Mahaffy now owns at least 250,000 options on the company.

Some additional info was provided as follows:

The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Clovis Oncology makes a similar move, sign up!

Other recent filings from the company include the following:
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020

Patrick J Mahaffy, Clovis Oncology's President and CEO and a director of the company, just received 250,000 options from the company. The strike price of the options received was $8.39, and these expire on February 03, 2030. Mahaffy now owns at least 250,000 options on the company.

Some additional info was provided as follows:

The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Clovis Oncology makes a similar move, sign up!

Other recent filings from the company include the following:
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
 Â

1. Name and Address of Reporting Person*
   MAHAFFY PATRICK J

(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100

(Street)
BOULDER
CO
80301 2. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
3. Date of Earliest Transaction (Month/Day/Year)
02/03/2020
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
MAHAFFY PATRICK J
(Last) (First) (Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER CO 80301
(City) (State) (Zip)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
   Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
   Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Stock Option (right to buy) $8.39 02/03/2020 A 200,000 (1) 02/03/2030 Common Stock 200,000 $0.00 200,000 D
Stock Option (right to buy) $8.39 02/03/2020 A 50,000 (2) 02/03/2030 Common Stock 50,000 $0.00 50,000 D
Explanation of Responses:

1. The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.

2. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.
   Remarks:

   /s/ Patrick J. Mahaffy 02/03/2020
   ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.